Prognostic Factors of Second-line Immune Checkpoint Inhibitors in Patients With Advanced-stage Non–Small Cell Lung Cancer: A Multicenter, Retrospective Study
Conclusion:
BMI and the number of metastatic sites were significantly associated with second-line ICI therapy outcomes in patients with NSCLC receiving first-line platinum-based chemotherapy.
Source: American Journal of Clinical Oncology - Category: Cancer & Oncology Tags: Original Articles: Thoracic Source Type: research
More News: Cancer | Cancer & Oncology | Chemotherapy | Lung Cancer | Non-Small Cell Lung Cancer | Study